Stan Gerson, MD
Director, Case CCC
Food Safety for Cancer Patients
We all worry about food safety issues in cancer patients. Issues relate to proper advice about food preferences, treatment food interactions, and food restrictions in immunosuppressive patients. An additional topic of importance is how to counsel patients in the setting of food recalls, and the real potential that cancer patients are at special risk.
The USDA Office of Public Affairs and Consumer Education recently collaborated with the FDA to prepare a publication on Food Safety for Cancer Patients. The publication is free, and can be either downloaded from the FDA website or ordered via email from email@example.com.
HPV Vaccination: A Significant Opportunity for Cancer Prevention
The following piece was written by Dr. Susan A. Flocke, Director of the Behavioral Measurement Core Facility and co-Leader of the Cancer Prevention, Control and Population Research Program of the Case Comprehensive Cancer Center. She is also Associate Professor of Family Medicine and Epidemiology & Biostatistics at CWRU.
The President's Cancer Panel monitors progress of the National Cancer Program, identifies topics of high importance to the nation, and recommends action to address identfied issues. Earlier this month, the Panel highlighted human papillomavirus (HPV) vaccines as an effective but under-used intervention to prevent cancers1.
Letters from the Panel were sent to multiple stakeholder organizations and to the President of the United States urging action to increase the uptake of HPV vaccination, especially in adolescents. The primary message of the calls to action is that HPV vaccination is cancer prevention and that the HPV vaccination is safe, effective, and especially important given the high prevalence of HPV.
In the United States, about 79 million people are currently infected with HPV and about 14 million become newly infected each year. More than 26,000 cancers each year are attributed to HPV, with cervical cancer in women accounting for most of these cases (10,300), followed by oropharyngeal cancer in men (6,700)2.
Currently, the Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for girls and boys at ages 11 and 12. For those who were not vaccinated at age 11-12, HPV vaccination is recommended for females ages 13 through 26 and males ages 13 through 21.
Cervarix and Gardasil are two HPV vaccines that are available for girls to protect against the HPV types that cause most cervical and anal cancers. Gardasil also protects against the HPV types that cause most genital warts; Gardasil is the only vaccine approved for boys. Both brands of HPV vaccine are given in three doses over six months.
Currently, only about 33% of US adolescent girls complete HPV vaccination3. Completion rates among boys is even lower at 7%. Unlike other types of vaccinations like Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) and MenACWY (meningococcal conjugate) that have improved in coverage since 2006, HPV uptake has been poor with coverage rates dropping from 2011 to 20123.
Factors associated with lack of uptake include lack of provider recommendation4,5 and parental concerns about side effects or potential harm to the child from the vaccine4.
Specific suggestions from the President's Cancer Panel1 for accelerating HPV vaccine uptake include:
Clinicians can immediately act by providing a consistent and focused message about HPV vaccination to age-eligible patients and parents. The American Academy of Family Physicians recently summarized what clinicians can tell parents when they express concerns about the vaccine for their child:
Increasing HPV vaccine uptake is a cancer prevention and public health priority. Action is required to change parental perception of the vaccine, increase its usage, prevent further spread of HPV.
1President's Cancer Panel, National Cancer Institute. (2014). President's Cancer Panel Annual Report 2012-2013.
2US Department of Health and Human Services, Centers for Disease Control and Prevention. (2013). Human papillomavirus (HPV)-associated cancers.
3US Department of Health and Human Services, Centers for Disease Control and Prevention. (2013). National and State Vaccination Coverage Among Adolescents Aged 13-17 Years –United States, 2012. Morbidity and Mortality Weekly Report62(34):685-693.
4Kester, LM, Zimet, GD, Fortenberry, JD, Kahn, JA, & Shew, ML. (2013). A National Study of HPV Vaccination of Adolescent Girls: Rates, Predictors, and Reasons for Non-Vaccination. Matern Child Health J, 17:879-885.
5Dorell, C, Yankey, D, & Strasser, S. (2011). Parent-reported reasons for nonreceipt of recommended adolescent vaccinations, National Immunization Survey–Teen, 2009. Clinical Pediatrics, 50(12), 1116-1124.
Teen Optimistic Heading into Fight with Cancer
The Blade - Feb 24, 2014
What Kayleen heard on Feb. 3 was that she had lung cancer. Last week it was revealed it is an extremely rare cancer called an inflammatory myofibroblastic tumor, or IMT. Doctors at the Cleveland Clinic are planning for a surgery in early March to remove the tumor. It is curable, according toDr. Nathan Pennell, a staff physician in the department of solid tumor oncology at the Cleveland Clinic. He said lung cancer is "incredibly" rare for teenagers, and patients with lung cancer have an average age of 70. IMT shows up in less than one percent of lung cancers, but is more common for those under 40, like Kayleen.
Head & Neck Cancer Research Findings: Longer survival for HPV-positive cancers, the benefits of outpatient care
The Plain Dealer - Feb 20, 2014
Two chemoradiation regimens used to treat late-stage head and neck cancer had the same outcomes, but at very different price points, according to research conducted at the Cleveland Clinic...For several years Dr. John Greskovich Jr. a radiation oncologist at the Clinic's Taussig Cancer Institute, has been part of a Clinic committee that focuses on cost management. Once the clinical portion of the study had ended in late 2012, Greskovich led a team that conducted a cost analysis using information from the patients’ treatment start date to six months post-treatment.
Cleveland Clinic Part of Study Testing New Imaging Technology to Help Avoid Unneeded Breast Biopsy
The Plain Dealer - Feb 19, 2014
Cleveland Clinic is one of 16 sites across the country testing a new technology that someday could help cut down on the number of invasive biopsies of breast masses that end up being noncancerous...The Clinic is part of the PIONEER-01 trial, sponsored by a San Antonio-based medical imaging company that has developed an imaging device it hopes will lower the number of unnecessary biopsies. The trial is designed to gauge the effectiveness of Imagio, created by Seno Medical Instruments Inc., which combines ultrasound with opto-acoustics, an imaging technology based on sound and light..."Based on the type of imaging that's currently available, a lot of benign images look like malignant images," said surgeon Dr. Stephen Grobmyer, Section Head of the Breast Center at the Cleveland Clinic...Grobmyer is the principal investigator of the trial at the Clinic, which has analyzed information from the breast masses of 26 patients to date; nationally just over 1,000 women are participating. The goal is to collect data from more than 2,000 patients across the country.
FDA approves Imbruvica for CLL
Helio/HemOnc Today - Feb 12, 2014
The FDA today granted accelerated approval to ibrutinib for use in patients with previously treated chronic lymphocytic leukemia...Mitchell R. Smith, MD, PhD, Director of lymphoid malignancies at Cleveland Clinic Taussig Cancer Institute, offers his perspective.
Molecular Imaging Probes Detect Brain Tumors and Dispersed Cells
Reuters - Feb 7, 2014
Imaging probes that detect a protein segment found in brain and other cancers have successfully detected glioblastomas and 99% of the invasive cells these tumors disperse, in preclinical studies presented this week. The probes may be able to tag cancer cells for MRI and also for real-time fluorescent imaging to guide surgery, researchers say. "We can see tumor cells down to the single-cell level with the probes," lead investigator Dr. Susann Brady-Kalnay of Case Western Reserve University in Cleveland, Ohio told Reuters Health by phone.
Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar
The Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar, will be held on February 26 at 4pm in the Global Cardiovascular Innovation Center, 10000 Cedar Avenue. This first seminar will feature a presentation by Dr. Goutham Narla, Assistant Professor, Medicine and Transformative Molecular Medicine at CWRU/UH, on Drugging the Undruggable: Small Molecule Activators of Tumor Suppressor Genes.
As part of the Case CCC Developmental Therapeutics Program, this series will gather clinicians, scientists, medical chemists, computer-aided drug designers, screeners, and commercialization personnel in the same room as a stimulating presentation so that all attendees can learn and benefit from the sparked interaction.
Retreat: Engaging in Cultural Competence through Awareness, Knowledge and Action
Please mark your calendars for Thursday, March 13 from 2-5 pm to join the Case Comprehensive Cancer Center and the Case Center for Reducing Health Disparities as they explore issues related to cultural competence. Extend your knowledge and raise your awareness about the dynamic variety of people and communities the Case CCC serves. This retreat will feature a keynote address by Dr. Sonja Harris-Haywood, and will provide perspective on the growing need to be culturally competent and facilitate the impact of cultural beliefs within the health care setting, specifically in research.
The retreat is intended for investigators, research nurses, regulatory coordinators, outreach and training and education personnel. Pre-registration by Friday, March 7 is required. Please direct any questions to Katarzyna Karelus at 216.844.4176 or firstname.lastname@example.org.
Lung Cancer Research Foundation
The Lung Cancer Research Foundation is accepting applications for its funding program. The Foundation funds research it believes will make major contributions toward better treatments, screening, and prevention of lung cancer.
Deadline: June 16, 2014
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Dan David Prize Scholarships
Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant
NIH BULLETIN – Notices and Funding Opportunities
Request For Information (RFI): Input on The Development of A Novel Drug Screening Program to Be Conducted at NCI's Drug Development Laboratories at The Frederick National Laboratory for Cancer Research (NOT-CA-14-032)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at email@example.com.
Genetics Student Seminar
Student, Genetics and Genome Sciences
Topic: Enhancer Dynamics of the Early Mammalian Embryo
11 am BRB 105
Pathology Research Seminar Series
PhD Candidate, Jackson lab, Pathology
Topic: The Roles of FAM83A and FAM83B in Mediating Resistance to ErbB Family Therapies
PhD Candidate, Scacheri lab, Pathology
Topic: Specific Alterations in the Enhancer Epigenome Mediate the Metastatic Phenotype in Osteosarcoma
12 pm WRB 1-413
Genomic Medicine Institute Seminar Series
Charis Eng, MD, PhD
Professor and Sondra J. and Stephen R. Hardis Endowed Chair in Cancer Genomic Medicine
Topic: PTEN Hamartoma Tumor Syndrome Previvors: What Now?!
12:30 pm NE1-205 Cleveland Clinic
Pathology Thesis Defense
PhD Candidate, Lederman lab, Pathology
Topic: The Impact of Inflammatory Cytokines IL-6 and IL-1B, on the Pathogenesis of Immune Failure in HIV Disease
3:30 pm WRB 1-413
Case CCC Breast Program Focus Group meeting
4 pm WRB 3-136
Physiology & Biophysics Seminar
Mark A. Lemmon, PhD
Chair, Biochemistry and Biophysics
George W. Raiziss Professor of Biochemistry and Biophysics
University of Pennsylvania
Topic: Diversity of Signaling Mechanisms in the Receptor Tyrosine Kinase Family
4 pm Robbins E-501
Radiation Oncology Grand Rounds
Andres Pinto, DMD, MPH
Chairman, Oral and Maxillofacial Medicine & Diagnostic Sciences
Associate Professor, Oral Medicine
Topic: Oral and Facial Complications of Head and Neck Radiation
8:10 am Lerner Tower B-151
Molecular Genetics Departmental Seminar
Graduate Student, Runge lab, Molecular Genetics
Topic: A Potential Synergistic Role for Histone H3 and H4 Acetylation in the DNA Damage Response
9:30 am NE1-205 Cleveland Clinic
Cellular and Molecular Medicine Seminar Series
Xinchun Pi, PhD
Research Instructor, Medicine
University of North Carolina at Chapel Hill
Topic: LRP1 is a Novel Regulator in Endothelial Cells
11 am NC1-202 Cleveland Clinic
Immunology Seminar Series
PhD Candidate, Cooper lab, Pathology
Topic Intermediate (CD14++CD16+) Monocytes Contribute to Doublet Formation and are Increased in Human Psoriatic Blood and Tissue
12 pm WRB 1-413
Cancer Biology Seminar
Andrew Bishop, PhD
Research Fellow, Sharifi lab, Cancer Biology
Topic: Development of LC-MS Methods to Analyze Androgen Metabolism in Prostate Cancer
2 pm NC1-202 Cleveland Clinic
Felicitas Lacbawan, MD
Director, Molecular Pathology,
SUNY Downstate Medical Center
Topic: Our Clinical Sequencing Initiative
4 pm NA5-03 Cleveland Clinic
Hematology and Oncology Division Research Conference
Evi Stavrou, MD
Assistant Professor, Div. of Hem/Onc
Topic: Factor XII: An Important Regulator of Leukocyte Function
8 am Lerner B-151
Pathology Grand Rounds
Audrey Schuetz, MD, MPH
Associate Director, Clinical Microbiology Services
Assistant Professor, Pathology & Laboratory Medicine
Weill Cornell Medical College/New York-Presbyterian Hospital
Topic: The Cat's Out Of The Bag: The Role Of Molecular Testing in Toxoplasmosis
8 am Pathology Amphitheatre
Neurosciences Guest Speaker Seminar
Jiri G. Safar, MD
Associate Professor, Pathology and Neurology
Co-Director, National Prion Disease Pathology Surveillance Center
Topic: Genetic and Epigenetic Determinants of Progression Rate in Neurodegenerative Disease
10 am NE1-205 Cleveland Clinic
Genetics and Genome Sciences Seminar
Drew Adams, PhD
HHMI Postdoctoral Associate
Center for the Science of Therapeutics
Topic: Small-molecule Modulators of Oxidative Stress and Ionizing Radiation Response
11 am BRB 105
Booki Min, PhD, DVM
Assistant Professor, Immunology
Topic: IL-27: More Than a Double-Edged Sword
12 pm NC1-202 Cleveland Clinic
Molecular Cardiology Faculty Seminar Series
Zheng-Rong Lu, PhD
Professor, Biomedical Engineering
Topic: Engineering Biomolecules for Drug Delivery and Imaging
3 pm NC1-202 Cleveland Clinic
Cancer Center Academic Drug Development Seminar
Goutham Narla, MD, PhD
Assistant Professor, Medicine and Transformative Molecular Medicine
Topic: Drugging the Undruggable: Small Molecule Activators of Tumor Suppressor Genes
4 pm Global Cardiovascular Innovation Center
Frontiers in Biological Sciences Lecture Series
Lynne E. Maquat, PhD
Professor, Biochemistry and Biophysics
University of Rochester
Topic: Tales from the Cellular Underworld: mRNA Decay and Disease
4 pm WRB 1-413
Molecular Genetics Midterm Review Seminar
Michelle Longworth, PhD
Assistant Staff, Molecular Genetics
Topic: Condensin II: Changing the Structure of the Genome to Defend Against Invaders
9:30 am NE1-205 Cleveland Clinic
Immunology Journal Club
Topic: 2B4 (CD244) Induced by Selective CD28 Blockade Functionally Regulates Allograft-specific CD8+ T Cell Responses
12 pm WRB 5-136
Molecular Biology and Microbiology Seminar
Erik Andrulis, PhD
Assistant Professor, Molecular Biology & Microbiology
Topic: The Yeast Mitochondrial Transcriptome
1 pm Rottman Seminar Room, Wood W203
Prostate Cancer Symposium
George Stark, PhD
Professor, Molecular Genetics, Lerner Research Institute
Topic: How Endogenous Interferons Affect Responses of Prostate Cancer to Therapy
Stefan Ambs, PhD, MPH
Senior Investigator Laboratory of Human Carcinogenesis
National Cancer Institute
National Institutes of Health
Topic: A Distinct Immune Signature in Prostate Tumors of African-American Men
Ralph R. Weichselbaum, MD
Chairman, Radiation and Cellular Oncology
University of Chicago
Topic: Jak–Stat/Cytoplasmic Sensors and Radioresistance
3 pm NE1-205 Cleveland Clinic
Hematology/Oncology Fellows Conference/Curriculum Series
8 am Breen Conference Rm.
Taussig Cancer Institute Grand Rounds
Karen Knudsen, PhD
Deputy Director for Basic Science
Professor, Cancer Biology
Jefferson University Kimmel Cancer Center
Topic: Hormone-DNA Repair Crosstalk in Prostate Cancer: Mechanisms and Implications for Therapeutic Intervention
8 am R3/002-003 Cleveland Clinic
Cellular and Molecular Medicine Seminar Series
Mark Lauer, PhD
Biomedical Engineering, Lerner Research Institute
Topic: Pathological Transformation of Hyaluronan Matrices by a Novel Transesterase: One Way Street, or are U-Turns Allowed?
10 am NC1-202 Cleveland Clinic
Cancer Center Seminar Series, co-sponsored by the Dept. of Biochemistry
Patricia K. Donahoe, MD
Marshall K. Bartlett Professor of Surgery
Harvard Medical School
Director, Pediatric Surgical Research Laboratories,
Massachusetts General Hospital
Topic: A Natural Reproductive Protein for Cancer, Contraception and Motor Neuron Diseases
12 pm BRB 105
Cancer Center Research in Progress
4 pm WRB 3-136
Screening for Cancer in Women: 2014
Embassy Suites - Rockside Rd. - Independence
Case CCC Annual Scientific Retreat
Wolstein Research Bldg/Corporate College East
1st Annual Multidisciplinary Colorectal Oncology Course
InterContinental Hotel & Bank of America Conference Center